MX367358B - Composiciones farmaceuticas que comprenden azd9291. - Google Patents

Composiciones farmaceuticas que comprenden azd9291.

Info

Publication number
MX367358B
MX367358B MX2016008744A MX2016008744A MX367358B MX 367358 B MX367358 B MX 367358B MX 2016008744 A MX2016008744 A MX 2016008744A MX 2016008744 A MX2016008744 A MX 2016008744A MX 367358 B MX367358 B MX 367358B
Authority
MX
Mexico
Prior art keywords
azd9291
pharmaceutical compositions
pharmaceutical
compositions
enamide
Prior art date
Application number
MX2016008744A
Other languages
English (en)
Other versions
MX2016008744A (es
Inventor
Wilson David
Finnie Cindy
Anthony Raw Steven
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50191689&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367358(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2016008744A publication Critical patent/MX2016008744A/es
Publication of MX367358B publication Critical patent/MX367358B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas adecuadas para la administración oral, y más particularmente con composiciones farmacéuticas, incluyendo composiciones de tabletas farmacéuticas, que contienen N-(2-{2-dimetilaminoetil-metilamino}-4-metoxi-5-{[4-(1-metilindol -3-il)pirimidin-2-il]amino}fenil)prop-2-enamida ("AZD9291 ") o una sal farmacéuticamente aceptable del mismo, en donde tales composiciones comprenden una cierta cantidad de celulosa microcristalina y al menos otro diluyente farmacéutico.
MX2016008744A 2014-01-02 2015-01-02 Composiciones farmaceuticas que comprenden azd9291. MX367358B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1400034.3A GB201400034D0 (en) 2014-01-02 2014-01-02 Pharmaceutical Compositions comprising AZD9291
PCT/GB2015/050001 WO2015101791A1 (en) 2014-01-02 2015-01-02 Pharmaceutical compositions comprising azd9291

Publications (2)

Publication Number Publication Date
MX2016008744A MX2016008744A (es) 2016-09-08
MX367358B true MX367358B (es) 2019-08-16

Family

ID=50191689

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008744A MX367358B (es) 2014-01-02 2015-01-02 Composiciones farmaceuticas que comprenden azd9291.

Country Status (37)

Country Link
US (5) US10183020B2 (es)
EP (1) EP3089741B1 (es)
JP (1) JP6588915B2 (es)
KR (1) KR102336378B1 (es)
CN (2) CN114712362A (es)
AR (1) AR098989A1 (es)
AU (1) AU2015204218B2 (es)
CA (1) CA2933403C (es)
CL (1) CL2016001609A1 (es)
CR (1) CR20160310A (es)
CY (1) CY1124848T1 (es)
DK (1) DK3089741T3 (es)
DO (1) DOP2016000156A (es)
EA (1) EA034243B9 (es)
ES (1) ES2873226T3 (es)
GB (1) GB201400034D0 (es)
GT (1) GT201600142A (es)
HK (1) HK1225655A1 (es)
HR (1) HRP20210749T1 (es)
HU (1) HUE054344T2 (es)
IL (1) IL246186B (es)
LT (1) LT3089741T (es)
MX (1) MX367358B (es)
MY (1) MY183536A (es)
NI (1) NI201600098A (es)
NZ (1) NZ721298A (es)
PE (1) PE20161170A1 (es)
PH (1) PH12016501310A1 (es)
PL (1) PL3089741T3 (es)
PT (1) PT3089741T (es)
RS (1) RS61927B1 (es)
SG (1) SG11201605339QA (es)
SI (1) SI3089741T1 (es)
TW (1) TWI702953B (es)
UY (1) UY35933A (es)
WO (1) WO2015101791A1 (es)
ZA (1) ZA201605300B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
AR110038A1 (es) 2016-05-26 2019-02-20 Kalyra Pharmaceuticals Inc Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
CN107176954B (zh) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
CN110013468B (zh) * 2018-01-09 2022-02-18 北京福元医药股份有限公司 一种azd9291氘代衍生物药物制剂
WO2019138346A1 (en) * 2018-01-10 2019-07-18 Alembic Pharmaceuticals Limited Pharmaceutical composition of osimertinib
CN116870008A (zh) 2018-02-12 2023-10-13 阿斯利康(瑞典)有限公司 用于治疗非小细胞肺癌的奧希替尼
CA3091707A1 (en) * 2018-03-01 2019-09-06 Astrazeneca Ab Pharmaceutical compositions comprising (2s)-n-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
KR102511672B1 (ko) 2018-03-23 2023-03-17 우시 상량 바이오테크놀로지 씨오., 엘티디. 의약 조성물, 그 제조방법 및 사용
JP2021530525A (ja) 2018-07-17 2021-11-11 インスメッド インコーポレイテッド ループス腎炎を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
JP2022526159A (ja) 2019-03-29 2022-05-23 アストラゼネカ・アクチエボラーグ 非小細胞肺がんの治療に使用するためのオシメルチニブ
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20230056604A1 (en) 2020-01-20 2023-02-23 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical preparations containing iftroban and methods for their preparation
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
JP4802436B2 (ja) * 2000-04-12 2011-10-26 Ｍｓｄ株式会社 口腔内崩壊型組成物及び口腔内崩壊型製剤
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
AU2003208444B2 (en) 2002-02-26 2006-10-26 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
CA2582299A1 (en) 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
EP1982718A4 (en) * 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd ANTICANCER PHARMACEUTICAL COMPOSITION
JP5576922B2 (ja) * 2006-04-20 2014-08-20 信越化学工業株式会社 腸溶性固体分散体を含んでなる固形製剤
EP2170062A4 (en) * 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
WO2012139736A1 (en) 2011-04-11 2012-10-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical composition comprising bosentan
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
HUE037645T2 (hu) * 2011-07-27 2018-09-28 Astrazeneca Ab Rák kezelésére alkalmas 2.(2,4,5-helyettesített-anilino)pirimidin származékok mint EGFR modulátorok
EP4218740A1 (en) * 2012-01-13 2023-08-02 XSpray Pharma AB (publ) Novel compositions
WO2013160916A1 (en) 2012-04-25 2013-10-31 Hetero Research Foundation Sunitinib malate solid dispersion
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291

Also Published As

Publication number Publication date
GT201600142A (es) 2019-08-12
CA2933403A1 (en) 2015-07-09
JP2017501201A (ja) 2017-01-12
SG11201605339QA (en) 2016-07-28
AR098989A1 (es) 2016-06-22
US20240189310A1 (en) 2024-06-13
DK3089741T3 (da) 2021-06-07
US20220395502A1 (en) 2022-12-15
PT3089741T (pt) 2021-06-11
PE20161170A1 (es) 2016-11-24
HRP20210749T1 (hr) 2021-06-25
KR20160101720A (ko) 2016-08-25
CL2016001609A1 (es) 2016-12-09
CN105848647A (zh) 2016-08-10
EP3089741A1 (en) 2016-11-09
CA2933403C (en) 2022-03-29
EA034243B9 (ru) 2020-04-10
EA034243B1 (ru) 2020-01-21
US20200360378A1 (en) 2020-11-19
EA201691242A1 (ru) 2016-12-30
MX2016008744A (es) 2016-09-08
ES2873226T3 (es) 2021-11-03
SI3089741T1 (sl) 2021-08-31
TW201609101A (zh) 2016-03-16
WO2015101791A1 (en) 2015-07-09
LT3089741T (lt) 2021-06-10
PH12016501310A1 (en) 2016-09-14
US20190111057A1 (en) 2019-04-18
NZ721298A (en) 2017-10-27
CN114712362A (zh) 2022-07-08
TWI702953B (zh) 2020-09-01
HK1225655A1 (zh) 2017-09-15
EP3089741B1 (en) 2021-03-10
AU2015204218B2 (en) 2017-06-15
CY1124848T1 (el) 2022-11-25
PL3089741T3 (pl) 2021-09-27
HUE054344T2 (hu) 2021-08-30
CN105848647B (zh) 2022-04-26
UY35933A (es) 2015-07-31
CR20160310A (es) 2016-09-23
GB201400034D0 (en) 2014-02-19
NI201600098A (es) 2016-12-20
AU2015204218A1 (en) 2016-07-07
US20160324854A1 (en) 2016-11-10
ZA201605300B (en) 2022-10-26
IL246186A0 (en) 2016-07-31
US10183020B2 (en) 2019-01-22
KR102336378B1 (ko) 2021-12-08
MY183536A (en) 2021-02-25
IL246186B (en) 2020-07-30
DOP2016000156A (es) 2016-08-15
RS61927B1 (sr) 2021-06-30
JP6588915B2 (ja) 2019-10-09

Similar Documents

Publication Publication Date Title
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
TN2016000491A1 (en) Carboxamide derivatives.
TN2016000489A1 (en) Carboxamide derivatives.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
PH12017501444A1 (en) (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
PH12019500567A1 (en) Crystalline forms
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
AU2015280874A1 (en) Novel heterocyclic compound
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
PH12017501832A1 (en) Stabilized pharmaceutical composition
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
PH12016502527B1 (en) Stabilized desmopressin
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
TR201721065A2 (tr) Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids

Legal Events

Date Code Title Description
FG Grant or registration